Earlier PBAC outcomes: committee rebuffs experts on Brenzys

Posted 19 August 2016

The PBAC has recommended PBS listing of Brenzys, MSD's biosimilar competition for Pfizer's Enbrel (etanercept) with an a-flag despite disquiet from clinicians.

The PBAC said it had recommended Brenzys on a cost minimisation basis for all adult indications currently covered by Enbrel.

To see the whole article please log in.

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Retype password

Not a member? Sign up here